-- Days : -- HRS : -- MIN : -- SEC
Register Now →
|Videos|October 29, 2019

Tesh Khullar on Keeping Up With Practice Transformation Under Value-Based Care

Learn what works and then try to apply it to your marketplace, explained Tesh Khullar, senior vice president and advisor, Flatiron Health.

Learn what works and then try to apply it to your marketplace, explained Tesh Khullar, senior vice president & advisor, Flatiron Health

Transcript

What are some best practices trying to keep up with practice transformation under value-based care?

I think learning and coming to meetings and learning what other practices are doing. We’re at the cutting edge of value-based care. You have groups like [South Carolina Oncology Associates] in South Carolina that are doing custom deals with their payers in their marketplace. Learning what’s working for other practices and then incorporating that and having a conversation with your payer about being the lower cost provider and what you can do to help the payer lower cost, which ultimately is going to lower cost for the patients, is what practices have to do. So, learn what works and then try to apply it to your marketplace, in particular.


Related to this article

Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel.  | Image: LinkedIn
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.